



# SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\*

## 上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)  
(於中華人民共和國註冊成立的股份有限公司)

(Stock code: 1877)

(股份代號 : 1877)

### NOTIFICATION LETTER 通知信函

28 September 2023

Dear registered shareholder,

**Shanghai Junshi Biosciences Co., Ltd.\* (the “Company”)  
Notice of Publication of the 2023 Interim Report (“Current Corporate Communication”)**

The English and Chinese versions of the Company’s Current Corporate Communication are available the websites of the Company ([www.junshipharma.com](http://www.junshipharma.com)) and The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)), or the arranged printed form(s) of Current Corporate Communication is enclosed (if applicable).

Shareholders may at any time choose to receive free of charge Corporate Communications<sup>(Note)</sup> either in printed form, or read the website version; and either in English language version only, Chinese language version only or both language versions, notwithstanding any wish to the contrary they have previously conveyed to the Company. If you want to receive another printed version of the Current Corporate Communication, please complete the Request Form printed on the reverse side and send it to the Company c/o Tricor Investor Services Limited (the “**H Share Registrar**”), using the mailing label and need not affix a stamp when returning (if posted in Hong Kong). Otherwise, please affix an appropriate stamp. The address of the H Share Registrar is 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. The Request Form may also be downloaded from the Company’s website at [www.junshipharma.com](http://www.junshipharma.com) or the HKEXnews’s website at [www.hkexnews.hk](http://www.hkexnews.hk).

If you would like to change your choice of language or means of receipt of the Company’s Corporate Communication in future, please complete the Request Form printed on the reverse side and send it to H Share Registrar, using the mailing label and need not affix a stamp when returning (if posted in Hong Kong). Otherwise, please affix an appropriate stamp. You may also send an email with a scanned copy of the completed and signed Request Form to [1877-ecom@hk.tricorglobal.com](mailto:1877-ecom@hk.tricorglobal.com). Even if you have chosen (or are deemed to have consented) to receive all future Corporate Communications via website version but for any reason you have difficulty in receiving or gaining access to the Current Corporate Communication, the Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2980 1333 during business hours from 9:00 a.m. to 5:00 p.m. from Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully  
By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
Chairman

*Note: Corporate Communications include but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) a reply slip.*

\* For identification purpose only.

Registered shareholder's information (Full name and address)

登記股東資料 (全名及地址)

REQUEST FORM 申請表格

To: Shanghai Junshi Biosciences Co., Ltd.\* (the "Company")
(Stock Code: 1877)
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

致: 上海君實生物醫藥科技股份有限公司 (「本公司」)
(股份代號: 1877)
經卓佳證券登記有限公司
香港夏愨道16號遠東金融中心17樓

I/We have already received a printed copy of the Current Corporate Communication in Chinese/English or have chosen (or are deemed to have consented) to read the Current Corporate Communication posted on the Company's website:

本人/我們已收取是次公司通訊之中文/英文印刷本或已選擇(或被視為已同意)瀏覽本公司網站所登載之是次公司通訊:

Part A I/We would like to receive a printed version of the Current Corporate Communication of the Company as indicated below:
甲部 本人/我們現希望以下列方式收取貴公司是次公司通訊之語言印刷本:

(Please mark a "✓" in ONLY ONE of the following boxes)
(請從下列選擇中,僅在其中一個空格內劃上「✓」號)

I/We would like to receive a printed copy in English.
本人/我們希望收取一份英文印刷本。

I/We would like to receive a printed copy in Chinese.
本人/我們希望收取一份中文印刷本。

I/We would like to receive both the printed English and Chinese copies.
本人/我們希望收取英文和中文各一份印刷本。

Part B I/We would like to change the choice of language(s) and/or means of receipt of future Corporate Communications of the Company as indicated below:
乙部 本人/我們現希望更改以下列方式收取 貴公司今後公司通訊之語言版本及/或收取方式:

(Please mark a "✓" in ONLY ONE of the following boxes)
(請從下列選擇中,僅在其中一個空格內劃上「✓」號)

to access all future Corporate Communications by electronic means through the Company's website instead of receiving printed copies, and receive an email notification to my/our email address below or a notification letter of the publication of the Corporate Communications on the Company's website; OR
透過本公司網站以電子方式瀏覽所有日後公司通訊以代替收取印刷本,並向本人/我們發出電郵通知(本人/我們之電郵地址如下)或就於本公司網站刊登公司通訊發出通知信函;或

Table with 12 empty cells for email address input.

(Please provide the email address in English Capital Letters and the email address will be used for email notification of the release of the Corporate Communications only. If no email address is provided, a printed notification letter of the posting of Corporate Communications on the website of the Company will be sent to you by post at your address as appearing in the Company's register of members.)

(請以英文正楷填寫電郵地址,有關電郵地址將僅用作收取公司通訊已發佈之電郵通知。如未有提供電郵地址,我們將透過郵寄方式,按閣下於本公司的股東名冊上所示之地址向閣下寄發有關公司通訊於本公司網站登載之通知信函之印刷本。)

to receive the printed English version of all future Corporate Communications ONLY; OR
僅收取所有日後公司通訊的英文印刷本;或

to receive the printed Chinese version of all future Corporate Communications ONLY; OR
僅收取所有日後公司通訊的中文印刷本;或

to receive both the printed English and Chinese versions of all future Corporate Communications.
同時收取所有日後公司通訊的英文及中文印刷本。

Registered shareholder's full name 登記股東全名: \_\_\_\_\_

Signature 簽名: \_\_\_\_\_

(Please use BLOCK LETTERS 請用正楷填寫)

Address 地址: \_\_\_\_\_

Contact telephone number 聯絡電話號碼: \_\_\_\_\_

Date 日期: \_\_\_\_\_

Notes 附註:

- 1. Please complete all your details clearly. 請閣下清楚填寫所有資料。
2. If your shares are registered in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Request Form in order to be valid. 如屬聯名股東,則本申請表格須由該名於本公司股東名冊上就聯名持有股份其姓名名列首位的股東簽署,方為有效。
3. Any form with more than one box marked (✓), with no box marked (✓), with no signature or otherwise incorrectly completed will be void. 如在本表格作出超過一項選擇,或未有作出選擇,或未有簽署,或在其他方面填寫不正確,則本表格將會作廢。
4. The above instruction will apply to the current and all future Corporate Communications to be sent to you until you notify to the Company c/o Tricor Investor Services Limited to the contrary or unless you have at any time ceased to have holdings in the Company. 上述指示適用於發送予閣下之是次及所有日後公司通訊,直至閣下通知本公司之H股股份過戶登記處卓佳證券登記有限公司另外之安排或任何時候停止持有本公司的股份。
5. For the avoidance of doubt, the Company does not accept any special instructions written on this Request Form. 為免存疑,任何在本申請表格上的額外手寫指示,本公司將不予處理。

Corporate Communications include but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meetings; (d) a listing document; (e) a circular; (f) a proxy form; and (g) a reply slip. 公司通訊包括但不限於:(a)董事會報告、年度賬目連同核數師報告及財務摘要報告(如適用);(b)中期報告及中期摘要報告(如適用);(c)會議通告;(d)上市文件;(e)通函;(f)代表委任表格;及(g)回條。

\* For identification purpose only
\* 僅供識別之用



Please cut the mailing label and stick it on an envelope to return this Reply Form to us.

No postage stamp is necessary if posted in Hong Kong.

閣下寄回此回條時,請將郵寄標籤剪貼於信封上。

如在香港投寄,毋須貼上郵票。



MAILING LABEL 郵寄標籤

Tricor Investor Services Limited
Freepost No. 10 GPO
Hong Kong
卓佳證券登記有限公司
簡便回郵號碼10 GPO
香港
上海君實生物醫藥科技股份有限公司(1877)